<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00898313</url>
  </required_header>
  <id_info>
    <org_study_id>VICC THO 0398</org_study_id>
    <secondary_id>P30CA068485</secondary_id>
    <nct_id>NCT00898313</nct_id>
  </id_info>
  <brief_title>Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer</brief_title>
  <official_title>Molecular Predictors of Lung Cancer Behavior</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Using samples of blood, urine, sputum, and lung tissue from patients at high risk
      of cancer for laboratory studies may help doctors learn more about changes that may occur in
      DNA and identify biomarkers related to cancer.

      PURPOSE: This research study is looking at molecular predictors of cancer in patients at high
      risk of lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To use fixed lung tissue for histological evaluation and fresh tissue samples for
           molecular studies to study DNA, RNA, and protein abnormalities in lung preneoplastic and
           neoplastic lesions.

        -  To use proteomic techniques, including matrix-assisted laser desorption ionization-mass
           spectrometry (MALDI-MS), to develop a method of diagnosing and staging both pre-invasive
           and invasive lesions, using less invasive methods.

      OUTLINE: Blood, urine, nasal cell, and sputum samples are collected. Lung tissue samples are
      also collected using fluorescence bronchoscopy and epithelial cell collection.

      Samples are studied by genetic and proteomic analyses, including comparative genomic
      hybridization, expression microarray, and protein profiling.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To quantitate the molecular changes during lung cancer development</measure>
    <time_frame>After collection of designated samples</time_frame>
    <description>As a part of the study nasal brushing specimens, sputum, blood, urine, and a small amount of other tissue will be collected during standard of care procedures (bronchial epithelial, trans-thoracic fine needle aspiration (FNA) and thoracentesis as part of patient work up.
Clinical diagnosis is the primary goal of the procedure. All the research specimens are collected after the primary goal of the procedure is met.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Develop a method to diagnose and stage pre-invasive and invasive lesions</measure>
    <time_frame>After collection of designated samples</time_frame>
    <description>Use of proteomic techniques in the laboratory to find a method of diagnosing lung tissue as benign or malignant rather than relying on invasive open-chest surgery for a diagnosis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Sample Collection</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>comparative genomic hybridization</intervention_name>
    <description>Collection of sputum, blood, urine, and a small amount of lung tissue.</description>
    <arm_group_label>Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression microarray analysis</intervention_name>
    <description>Collection of sputum, blood, urine, and a small amount of lung tissue.</description>
    <arm_group_label>Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling analysis</intervention_name>
    <description>Collection of sputum, blood, urine, and a small amount of lung tissue.</description>
    <arm_group_label>Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biologic sample preservation procedure</intervention_name>
    <description>Collection of sputum, blood, urine, and a small amount of lung tissue.</description>
    <arm_group_label>Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nasal brushing</intervention_name>
    <description>Using a brush, superficial cells are removed from the nose.</description>
    <arm_group_label>Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>Venous blood will be collected</description>
    <arm_group_label>Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Urine collection</intervention_name>
    <description>Subjects will be asked to provide a urine specimen.</description>
    <arm_group_label>Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sputum sample</intervention_name>
    <description>Prior to their bronchoscopy, subjects will be asked for a sputum specimen. This is a collection of mucous that you cough up.</description>
    <arm_group_label>Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fluorescence bronchoscopy with airway biopsy</intervention_name>
    <description>A flexible tube attached to a fluorescent light source will be inserted into the subject's mouth or nose to reach the airway. Samples of the lining of the airway will be taken, as well as bronchial secretions and epithelial cell from brushings of the lining of the airway.</description>
    <arm_group_label>Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fine needle aspiration of the lung</intervention_name>
    <description>A small needle is inserted into the lung to collect tissue. This procedure will only be performed if the patient's physician orders it.</description>
    <arm_group_label>Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>thoracentesis</intervention_name>
    <description>A small needle is inserted into the patient's lung cavity and a small amount of fluid is collected. This procedure will only be performed if the patient's physician orders it.</description>
    <arm_group_label>Sample Collection</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine, nasal cells, sputum, bronchal epithelial cells, airway tissue, and lung tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        People who may have lung cancer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -All adults referred to Vanderbilt Medical Center, Veterans Administration Medical Center,
        St. Thomas Hospital and Meharry Medical Center for evaluation of signs or symptoms of lung
        cancer.

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Minors

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre P. Massion, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanderbilt Ingram Clinical Trials Information Program</last_name>
    <phone>1-800-811-8480</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VICC Clinical Trials Information Program</last_name>
      <phone>800-811-8480</phone>
      <email>cip@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Pierre Massion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Office</last_name>
      <phone>615-873-8066</phone>
    </contact>
    <contact_backup>
      <last_name>Rena Burns, RN</last_name>
      <phone>(615) 873-7658</phone>
      <email>Rena.Burns@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre Massion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vicc.org/ct/</url>
    <description>Vanderbilt-Ingram Cancer Center, Find a Clinical Trial</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Pierre P. Massion, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine (Allergy, Pulmonary &amp; Critical Care) and Cancer Biology; Pulmonary and Critical Care Medicine Doctor</investigator_title>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

